Use of a Novel Study Insight Analytics (SIA) Methodology to Improve PANSS Data Quality and Signal Detection in a Global Clinical Trial in Schizophrenia

Authors

M Opler, WCG Inc., New York, NY, USA. Electronic address: mark.opler@panss.org.
S Negash, WCG Inc., New York, NY, USA.
K Tatsumi, WCG Inc., New York, NY, USA.
C Liu, WCG Inc., New York, NY, USA.
M Komaroff, Noven Pharmaceuticals, Inc., Jersey City, NJ, USA.
G Capodilupo, WCG Inc., New York, NY, USA.
M Hasebe, Hisamitsu Pharmaceutical Co., Inc., Tosu, Japan.
B Echevarria, WCG Inc., New York, NY, USA.
R Blattner, WCG Inc., New York, NY, USA.
L Citrome, New York Medical College, New York, NY, USA.Follow

Author Type(s)

Faculty

DOI

10.1016/j.schres.2024.03.052

Journal Title

Schizophrenia Research

First Page

239

Last Page

246

Document Type

Article

Publication Date

5-1-2024

Department

Psychiatry and Behavioral Sciences

Disciplines

Medicine and Health Sciences

Recommended Citation

Opler, M., Negash, S., Tatsumi, K., Liu, C., Komaroff, M., Capodilupo, G., Hasebe, M., Echevarria, B., Blattner, R., & Citrome, L. (2024). Use of a Novel Study Insight Analytics (SIA) Methodology to Improve PANSS Data Quality and Signal Detection in a Global Clinical Trial in Schizophrenia. Schizophrenia Research, 267, 239-246. https://doi.org/10.1016/j.schres.2024.03.052